AdipoGen Life Sciences

anti-Vaspin (human), pAb

CHF 450.00

In stock

AG-25A-0048-C100100 µgCHF 450.00

Figure 1: Western blot analysis using anti-Vaspin (human), pAb (Prod. No. AG-25A-0048) at 1:2'000 dilution.
1: Human Vaspin (His-tagged).
2: Human Vaspin (FLAG^®-tagged).
3: Mouse IL-33 (His-tagged) (negative control).

Specifications / Handling

More Information
Product Details
Synonyms	Visceral Adipose Tissue-derived Serine Protease Inhibitor; Serpin A12; OL-64
Product Type	Polyclonal Antibody
Properties
Source/Host	Rabbit
Immunogen/Antigen	Recombinant human vaspin.
Application	ELISA: (direct and indirect: 1:2’000-1:5’000) Western Blot: (1:2’000-1:5’000 using ECL; suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk; suggested incubation time is 1 hour at room temperature). Optimal conditions must be determined individually for each application.
Crossreactivity	Human
Specificity	Recognizes human vaspin. Detects a band of ~48kDa by Western blot.
Purity Detail	Protein A-affinity purified.
Concentration	1mg/ml
Formulation	Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Isotype Negative Control	Rabbit IgG
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 6 months after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Vaspin (Visceral adipose tissue-derived serpin; Serpin A12), a serine protease inhibitor (serpin), is an insulin-sensitizing adipocytokine that has been isolated from both visceral and subcutaneous white adipose tissue. Based on recent findings, vaspin is suggested to regulate immune responses and inflammation and was found to be correlated with various metabolic parameters. Vaspin may represent a novel biomarker for obesity and impaired insulin sensitivity and might serve as a new therapeutic target of metabolic syndrome.

Call	+41 61 926 6040
Fax	+41 61 926 6049